Sumatriptan transmucosal - BDSI
Alternative Names: Transmucosal sumatriptan - BDSILatest Information Update: 24 Mar 2022
At a glance
- Originator QLT USA
- Class Antimigraines; Indoles; Small molecules; Sulfonamides; Tryptamines
- Mechanism of Action 5-HT1 serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Migraine
Most Recent Events
- 22 Mar 2022 BioDelivery Sciences International has been acquired by Collegium Pharmaceutical
- 17 Aug 2006 Discontinued - Preclinical for Migraine in USA (Transmucosal)
- 22 Nov 2004 Atrix Laboratories has been acquired by QLT